Financial Report: Amgen 2Q

Amgen 2Q

2Q Revenues: $3.8 billion (+3%)

2Q Earnings: $1.2 billion (-5%)

YTD Revenues: $7.4 billion (+6%)

YTD Earnings: $2.4 billion (+4%)

Comments: Total product sales for the quarter were $3.6 billion (-1%). Sales in the U.S. totaled $2.8 billion (-2%) and International sales were up 3% to $826 million. U.S. product sales in the quarter include a $45 million unfavorable impact for certain U.S. Health Care Reform Legislation provisions. Worldwide sales of Aranesp were down 13% to $603 million due to decline in demand. Sales of Epogen were $657 million (+3%). Combined worldwide sales of Neulasta and Neupogen were up 1% to $1.2 billion in the quarter. Sales of Enbrel were $877 million (-2%). Worldwide sales of Sensipar were $172 million (+3%).